Immunome Receives FDA Clearance For Its Investigational New Drug Application For IM-1340 To Treat Advanced Solid Tumors

Immunome, Inc. (NASDAQ: IMNM) has received FDA clearance for its Investigational New Drug application for IM-1340, an antibody-drug conjugate aimed at treating advanced solid tumors. This marks a significant step for the clinical-stage oncology company in its efforts to develop targeted cancer therapies.